Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationLong-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. 2016, 51 (6):745-52 Scand. J. Gastroenterol.
AbstractAntimitochondrial antibodies (AMA) are a sensitive and specific marker for primary biliary cirrhosis (PBC). AMAs are present in 95% of patients with PBC. However, 5% do not have AMAs and data on these patients is scarce. We aim to evaluate the long-term outcomes of patients with AMA negative PBC.
A retrospective chart review of 71 AMA negative PBC patients. Disease presentation, laboratory results, and clinical endpoints were recorded. AMA negative patients were matched on year of diagnosis to a control group of 71 AMA positive patients.
Ninety-six percent of the AMA negative patients were of female gender with a median age at diagnosis of 55 years and a length of follow-up of 7.5 years vs. 86% females, a median age of 56 and a follow-up of 8.3 years in the control group. Mean total bilirubin and alkaline phosphatase levels were 0.7 mg/dL vs. 0.6 and 570 U/L vs 341, in AMA negative vs. AMA positive patients at presentation, respectively (p = NS). AMA negative patients did not differ in terms of age, serum IgM levels, ANA status, or length of follow-up. Notably, AMA negative patients had a significantly reduced survival free of liver-related complications including transplantation and death compared to AMA positive patients (p = 0.0182).
In this large experience, AMA negative PBC patients had a significantly worse prognosis compared to AMA positive PBC patients. The reason for the difference in prognosis is unclear, as it may be true difference or reflect delays in case detection among AMA negative patients.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Scandinavian journal of gastroenterology
- Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.
- Authors: Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M
- Issue date: 1997 May
- Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?
- Authors: Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R
- Issue date: 2002 Apr
- Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis.
- Authors: Zhang FK, Jia JD, Wang BE
- Issue date: 2004 May
- Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis.
- Authors: Liu B, Shi XH, Zhang FC, Zhang W, Gao LX
- Issue date: 2008 Feb
- Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
- Authors: Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD
- Issue date: 1997 Jul